Liver Stiffness Linked to Hepatic Events, Death in Hepatitis B

This article originally appeared here.
Share this content:
Liver Stiffness Linked to Hepatic Events, Death in Hepatitis B
Liver Stiffness Linked to Hepatic Events, Death in Hepatitis B

MONDAY, Oct. 17, 2016 (HealthDay News) -- For patients with chronic hepatitis B (CHB), liver stiffness measurement (LSM) is associated with hepatic events and death, while metabolic syndrome increases the risk of cardiovascular events, according to a study published online Oct. 1 in Hepatology.

Jenny Yeuk-Ki Cheng, from the Chinese University of Hong Kong, and colleagues recruited 1,466 CHB patients for LSM with transient elastography and detailed metabolic profiling. Patients were followed for any clinical event.

The researchers found that 93 and 44 patients developed hepatic and cardiovascular events, respectively, at a mean follow-up of 88 ± 20 months; 70 patients died. The cumulative probability of hepatic events was higher for patients with baseline LSM >8.0 kPa versus ≤8.0 kPa at eight years (12.3 versus 3.1 percent; P < 0.001). The cumulative probability of cardiovascular events was higher for patients with metabolic syndrome (8.0 versus 2.1 percent; P < 0.001). High LSM had no impact on cardiovascular events, and metabolic syndrome had no effect on hepatic events. LSM >8.0 kPa was an independent risk factor for death (adjusted hazard ratio, 1.9; 95 percent confidence interval, 1.1 to 3.2); metabolic syndrome was not (adjusted hazard ratio, 1.3; 95 percent confidence interval, 0.8 to 2.4).

"Metabolic syndrome increased the risk of cardiovascular events but not hepatic events and death; LSM was the important risk factor of hepatic events and death in CHB patients," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Low-Dose Hyaluronidase Can Remove Hyaluronic Acid Fillers

Greater resolution of nodules with hyaluronidase versus saline; more rapid resolution with higher doses

Improvement in Race-Based Disparities in Years of Life Lost

Improvement in Race-Based Disparities in Years of Life ...

Decline in race-based disparities in years of life lost seen in the United States from 1990 to 2014

Drug-Related Endocarditis Cases Up From 2007 to 2015

Drug-Related Endocarditis Cases Up From 2007 to 2015

Increase in endocarditis over nine-year study period mirrored increase in concomitant mixed drug use

is free, fast, and customized just for you!

Already a member?

Sign In Now »